

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3551722

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	4	
CONVEYING PARTY DATA		
	Name	Execution Date
	CENES PHARMACEUTICALS, INC.	02/28/2003
RECEIVING PARTY DATA		
Name:	ACORDA THERAPEUTICS, INC.	
Street Address:	15 SKYLINE DRIVE	
City:	HAWTHORNE	
State/Country:	NEW YORK	
Postal Code:	10532	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14844475
CORRESPONDENCE DATA		
Fax Number:	(617)542-2241	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(617) 542-6000	
Email:	jfoley@Mintz.com	
Correspondent Name:	SHOVON ASHRAF	
Address Line 1:	ONE FINANCIAL CENTER	
Address Line 2:	MINTZ LEVIN	
Address Line 4:	BOSTON, MASSACHUSETTS 02111	
ATTORNEY DOCKET NUMBER:	43509-501C03US	
NAME OF SUBMITTER:	SHOVON ASHRAF	
SIGNATURE:	/Shovon Ashraf/	
DATE SIGNED:	10/01/2015	
Total Attachments: 4		
source=Assignment Cenes to Acorda#page1.tif		
source=Assignment Cenes to Acorda#page2.tif		
source=Assignment Cenes to Acorda#page3.tif		
source=Assignment Cenes to Acorda#page4.tif		

COPY

ASSIGNMENT OF INVENTION

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR: CeNeS Pharmaceuticals plc
Compass House, Vialon Park
Chivers Way, Histon
Cambridge CB4 9ZR
UK

(If assignment is by person or entity to whom invention was previously assigned and this was recorded in PTO add the following)

Recorded on: _____

Reel: _____

Frame: _____

Hereby sell, assign and transfer to

ASSIGNEE: Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne, New York 10532
U.S.A.

And the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest, including the right to sue for present, past and future infringement, in the United States, its territorial possessions, and in all foreign countries, including all treaty and convention rights in and to the invention and any and all improvements of the patents and patent applications listed on Schedule A attached hereto;

And any legal equivalent thereof in a foreign country, and, in and to, all United States and foreign Letters Patent, for the full term thereof, to be obtained for said invention by the above application or any continuation, division, renewal, extension or substitute thereof, and as to letters patents any re-issue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all such Letters Patent to ASSIGNEE:


ASSIGNOR further covenants to promptly provide all pertinent facts and documents known and accessible to ASSIGNOR relating to said invention and said Letters Patent and legal equivalents; to testify as to the same in any interference, litigation or proceeding related thereof; to execute and deliver any and all papers that may be necessary or desirable to perfect the title to said invention or any Letters Patents which may be granted therefore in said ASSIGNEE, its

successors, assigns or other legal representatives; to execute any additional or divisional applications for patents for said invention or any part or parts thereof, and for the release of any Letters Patents to be granted therefore; and to make all rightful oaths and do all lawful acts requisite for procuring the same or for aiding therein, all without further compensation, but at the sole expense of ASSIGNEE, its successors, assigns, or other legal representatives.

ASSIGNORS hereby grants ASSIGNEE and Assignee's attorneys the power to insert the Serial No. and/or filing date of the above-described application(s) after such information becomes known to them.

IN WITNESS WHEREOF, I have hereunto set hand and seal.

ASSIGNOR:



Dated: 28-02-07

SCHEDULE A

U.S. Patent No.	Issue Date	Title	Inventor(s)
✓ 5,530,109	06/25/1996	DNA ENCODING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
✓ 5,602,086	02/11/1997	METHOD OF USING A SECRETABLE GLIAL MITOGENIC FACTOR TO INDUCE ACETYLCHOLINE RECEPTOR SYNTHESIS	A. Goodearl et al.
6,147,190	11/14/2000	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,854,220	12/29/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,792,849	08/11/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,621,081	04/15/1997	GLIAL MITOGENIC FACTORS	A. Goodearl et al.
✓ 5,606,032	07/25/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 6,232,286	05/15/2001	METHOD OF STIMULATING MITOGENESIS IN GLIAL CELLS USING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
✓ 6,194,177	02/27/2001	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,716,930	02/10/1998	GLIAL GROWTH FACTORS	A. Goodearl et al.
✓ 6,204,241	03/20/2001	METHODS FOR TREATING NERVOUS SYSTEM PATHOPHYSIOLOGIES USING GLIAL GROWTH FACTORS	A. Goodearl et al.
✓ 6,144,642	09/03/2002	METHODS OF INCREASING MYOTUBE FORMATION OR SURVIVAL OF MUSCLE CELL MITOGENESIS, DIFFERENTIATION OR SURVIVAL USING A NEUREGULIN	Robert Sklar et al.
✓ 5,594,114	01/14/1997	SCHWANN CELL MITOGENIC FACTOR, ITS PREPARATION AND USE	A. Goodearl et al.
✓ 6,087,323	07/11/2000	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	David Gwynne et al.
✓ 5,876,973	03/02/1999	METHOD FOR MAKING ANTIBODIES WHICH SPECIFICALLY BIND TO GLIAL GROWTH FACTORS	David Gwynne et al.

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
✓ 08/471,833	06/06/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/730,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/736,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/734,592	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/736,070	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/472,065	06/06/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/735,010	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/469,549	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,665	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.

SCHEDULE A (Continued)

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
00/461,097	06/05/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	A. Sklar et al.
08/468,731	06/06/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/411,295	03/27/1995	METHODS FOR TREATING DISORDERS OF THE MYO	T.A. Reh ET AL.
09/069,784	03/20/2001	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/366,886	08/04/1999	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/298,121	04/23/1999	METHODS FOR TREATING CONGESTIVE HEART FAILURE	K. HIRKER-BRADY ET AL.
09/530,884	10/18/1998	THERAPEUTICS METHODS COMPRISING USE OF A NEUREGULIN	R.N. MCBURNEY ET AL.